| Literature DB >> 28573044 |
Jing-Jing Rong1, Dan Liu1, Ming Liang1, Qing-Hua Wang2, Jing-Yang Sun1, Quan-Yu Zhang1, Cheng-Fei Peng1, Feng-Qi Xuan1, Li-Jun Zhao1, Xiao-Xiang Tian1, Ya-Ling Han1.
Abstract
BACKGROUND: Splenic artery embolization (SAE) has been an effective adjunct to the Non-operative management (NOM) for blunt splenic injury (BSI). However, the optimal embolization techniques are still inconclusive. To further understand the roles of different embolization locations and embolic materials in SAE, we conducted this system review and meta-analyses.Entities:
Keywords: Blunt splenic injury; Clinical outcome; Embolization; Location; Material
Mesh:
Year: 2017 PMID: 28573044 PMCID: PMC5450228 DOI: 10.1186/s40779-017-0125-6
Source DB: PubMed Journal: Mil Med Res ISSN: 2054-9369
Clavien-Dindo classification of morbidity for complication
| Grade I | Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions |
| Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside | |
| Grade II | Requiring pharmacological treatment with drugs other than those allowed for grade I complications |
| Blood transfusions and TPN1 are also included | |
| Grade III | Requiring surgical, endoscopic or radiological intervention |
| IIIa | Intervention not under general anesthesia |
| IIIb | Intervention under general anesthesia |
| Grade IV | Life-threatening complication (including CNS complications) or requiring IC/ICU-management |
| IVa | Single organ dysfunction (including dialysis) |
| IVb | Multi-organ dysfunction |
| Grade V | Death |
Fig. 1Flow diagram of study identification
Quality assessment of studies in 2nd study set for meta-analyses using Newcastle-Ottawa Scale
| Author | Year | Selection | Compatibility | Outcomes | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |||
| Liu et al.[ | 2004 | ▲ | ▲ | ▲ | - | ▲▲ | ▲ | ▲ | ▲ | 8 |
| Franco et al.[ | 2011 | ▲ | ▲ | ▲ | - | ▲ | ▲ | ▲ | ▲ | 7 |
| Wu et al. [ | 2011 | ▲ | ▲ | ▲ | - | ▲ | ▲ | ▲ | ▲ | 7 |
| Smith et al.[ | 2006 | ▲ | ▲ | ▲ | - | ▲ | ▲ | ▲ | ▲ | 7 |
| Haan et al.[ | 2004 | ▲ | ▲ | ▲ | - | ▲ | ▲ | ▲ | ▲ | 7 |
| Ekeh et al.[ | 2005 | ▲ | ▲ | ▲ | - | ▲ | ▲ | ▲ | ▲ | 7 |
| Wu et al.[ | 2008 | ▲ | ▲ | ▲ | - | ▲ | ▲ | ▲ | ▲ | 7 |
| Killeen et al.[ | 2001 | ▲ | ▲ | ▲ | - | ▲ | ▲ | ▲ | ▲ | 7 |
| Gaarder et al.[ | 2006 | ▲ | ▲ | ▲ | - | ▲▲ | ▲ | ▲ | ▲ | 8 |
| Cooney et al.[ | 2005 | ▲ | ▲ | ▲ | - | ▲▲ | ▲ | ▲ | ▲ | 8 |
▲one point
▲▲two points
Demographic characteristics of included studies
| Author |
| Average age (year) | Male/Female | AAST | Indication [ | |||
|---|---|---|---|---|---|---|---|---|
| Contrast blush | Pseudoaneurysm | Large hemoperitoneum | AAST III-V | |||||
| Niloy et al.[ | 45 | 48.0 | 28/17 | 3.0 | 27 (60.0) | 7 (15.6) | 0 (0) | 31 (68.9) |
| Liu et al.a [ | 6 | 43.8 | 4/2 | 3.7 | 2 (33.3) | 0 (0) | 3 (50.0) | 6 (100.0) |
| Ekeh et al. [ | 88 | 37.8 | 59/29 | 3.4 | 17 (19.3) | 21 (23.9) | 0 (0) | 79 (89.8) |
| Liu et al. [ | 15 | - | - | 3.4 | - | - | - | - |
| Franco et al.a [ | 14 | 44.8 | 13/1 | 3.1 | 8 (57.1) | - | - | 6 (42.9) |
| Wu et al.a [ | 53 | 37.5 | 33/20 | 3.3 | 33 (62.3) | 11 (20.8) | 0 (0) | - |
| Smith et al.a [ | 41 | - | - | 3.1 | - | - | - | 27 (65.9) |
| Haan et al.a [ | 140 | 33.0 | 106/34 | 3.5 | 107 (76.4) | 0 (0) | 9 (6.4) | 87 (62.1) |
| Ekeh et al.a [ | 15 | 36.0 | 11/4 | 3.5 | 8 (53.3) | - | - | 14 (93.3) |
| Wu et al.a [ | 19 | 46.5 | 11/8 | 3.5 | 8 (42.1) | 1 (5.3) | 10 (52.6) | 19 (100.0) |
| Edmund et al. [ | 8 | 35.1 | 7/1 | 4.5 | 5 (62.5) | 0 (0) | 0 (0) | 8 (100.0) |
| Ashraf et al [ | 109 | - | - | - | - | - | - | - |
| Kaseje et al. [ | 11 | 32.7 | - | - | 11 (100.0) | 0 (0) | 0 (0) | - |
| Haan et al. [ | 32 | - | - | - | 0 (0) | 32 (100.0) | 0 (0) | - |
| Wu et al. [ | 10 | - | - | - | 8 (80.0) | 0 (0) | 2 (20.0) | - |
| Bessoud et al. [ | 37 | 40.0 | 28/9 | 3.7 | 14 (37.8) | 0 (0) | 34 (91.9) | - |
| Killeen et al.a [ | 53 | 37.6 | - | 3.2 | - | - | - | 42 (79.2) |
| Sclafani et al. [ | 60 | 33.9 | 45/15 | 2.9 | - | - | - | 38 (63.3) |
| Sclafani et al. [ | 18 | - | - | - | 18 (100.0) | 0 (0) | 0 (0) | - |
| Gaarder et al.a [ | 27 | 31.0 | 21/6 | 3.1 | 14 (51.9) | 0 (0) | 11 (40.7) | 7 (25.9) |
| Cooney et al.a [ | 9 | 39.0 | 6/3 | 3.2 | 6 (66.7) | 0 (0) | 0 (0) | 9 (100.0) |
| Hagiwara et al. [ | 15 | 36.0 | 11/4 | 4.0 | 15 (100.0) | 0 (0) | 6 (40.0) | 15 (100.0) |
| Wei et al. [ | 51 | 47.0 | - | 3.8 | 35 (68.6) | 0 (0) | 23 (45.1) | 51 (100.0) |
| Total | 876 | 38.8 | 634/242 | 3.4 | 336 (38.4) | 72 (8.2) | 158 (18.0) | 439 (50.1) |
aStudy in 2nd study set
“-”not mentioned; AAST: Grades of American Association for the Surgery of Trauma-Organ Injury Scale
Details of the included studies
| Author |
| SAE site ( | SAE material ( | Primary success [ | Severe complication [ | DC III [ | |||
|---|---|---|---|---|---|---|---|---|---|
| P | D | P + D | Coil | Gelfoam | |||||
| Niloy et al. [ | 45 | 9 | 34 | 2 | 21 | 5 | 41 (91.1) | 13 (28.9) | 3 (6.7) |
| Liu et al. a [ | 6 | 0 | 6 | 0 | 5 | 1 | 5 (83.3) | 0 (0) | 1 (16.7) |
| Ekeh et al. [ | 88 | 51 | 22 | 15 | 88 | 0 | 84 (95.5) | 8 (9.1) | 0 (0) |
| Liu et al. [ | 15 | - | - | - | 0 | 0 | 12 (80.0) | 1 (6.7) | 0 (0) |
| Franco et al. a[ | 14 | 8 | 6 | 0 | 12 | 1 | 13 (92.9) | 1 (7.1) | 0 (0) |
| Wu et al. a[ | 53 | 5 | 48 | 0 | 24 | 29 | 44 (83.0) | 14 (26.4) | 0 (0) |
| Smith et al.a [ | 41 | 27 | 9 | 5 | 22 | 2 | 30 (73.0) | 12 (29.3) | 12 (29.3) |
| Haan et al.a [ | 140 | - | - | - | 83 | 48 | 122 (87.1) | 38 (27.1) | 3 (2.1) |
| Ekeh et al. a[ | 15 | 10 | 1 | 4 | - | - | 14 (93.3) | 1 (6.7) | 0 (0) |
| Wu et al.a [ | 19 | 3 | 16 | 0 | 0 | 16 | 14 (74.0) | 7 (36.8) | 5 (26.3) |
| Edmund et al. [ | 8 | 3 | 0 | 5 | - | - | 8 (100.0) | 1 (12.5) | 1 (12.5) |
| Ashraf et al. [ | 109 | 109 | 0 | 0 | 109 | 0 | 102 (93.6) | 7 (6.4) | 0 (0) |
| Kaseje et al. [ | 11 | 8 | 3 | 0 | - | - | 8 (72.7) | 3 (27.3) | 3 (27.3) |
| Haan et al. [ | 32 | 32 | 0 | 0 | 32 | 0 | 29 (90.1) | 3 (9.4) | 3 (9.4) |
| Wu et al. [ | 10 | 3 | 7 | 0 | 0 | 10 | 8 (80.0) | 9 (90.0) | 2 (20.0) |
| Bessoud et al. [ | 37 | 37 | 0 | 0 | 37 | 0 | 36 (97.0) | 1 (2.7) | 1 (2.7) |
| Killeen et al.a [ | 53 | 24 | 22 | 7 | - | - | 47 (88.7) | 43 (81.1) | 3 (5.7) |
| Sclafani et al. [ | 60 | 60 | 0 | 0 | 60 | 0 | 57 (95.0) | 5 (8.3) | 3 (5.0) |
| Sclafani et al. [ | 18 | 17 | 0 | 1 | 18 | 0 | 18 (100) | 1 (5.6) | 0 (0) |
| Gaarder et al. a[ | 27 | 21 | 2 | 4 | - | - | 26 (96) | 1 (3.7) | 0 (0) |
| Cooney et al.a [ | 9 | 6 | 3 | 0 | - | - | 6 (67) | 3 (33.3) | 0 (0) |
| Hagiwara et al. [ | 15 | 9 | 1 | 5 | - | - | 15 (100) | 5 (33.3) | 1 (6.7) |
| Wei et al.[ | 51 | 14 | 37 | 0 | - | - | 50 (98) | 2 (3.9) | 15 (29.4) |
| Total | 876 | 456 | 217 | 48 | 511 | 112 | 789 (90.1) | 179 (20.4) | 56 (6.4) |
aStudy in 2nd study set; SAE. Splenic artery embolization; P. Proximal splenic artery embolization; D. Distal splenic artery embolization; P + D: Combination of proximal and distal splenic artery embolization; DC III: Clavien-Dindo classification of morbidity for complication III; “-”Not mentioned
Comparisons of clinical outcomes between proximal vs distal and combined embolization in 1st and 2nd study sets
| Outcome | Study set | Location | Percentage (%) |
|
|
|---|---|---|---|---|---|
| Success rate | 1st | P | 91.4 (444/486) | 0.11a | 1.49 (0.91–2.45) |
| P | 91.4 (444/486) | 0.27a | 1.67 (0.67–4.18) | ||
| 2nd | P | 85.0 (122/142) | 0.52a | 1.28 (0.61–2.67) | |
| P | 86.7 (104/120) vs 72.2 (13/18) | 0.11a | 2.56 (0.81–8.05) | ||
| Severe complication | 1st | P | 10.7 (50/466) vs 30.7 (67/218) | <0.01a | 0.27 (0.18–0.41) |
| P | 10.7 (50/466) vs 35.6 (16/45) | <0.01a | 0.22 (0.11–0.43) | ||
| 2nd | P | 18.2 (24/132) vs 28.7 (31/108) | 0.05 | 0.51 (0.26–1.00) | |
| P | 20.2 (23/114) vs 58.8 (10/17) | 0.00 | 0.10 (0.03–0.36) | ||
| DC III | 1st | P | 7.3 (32/438) vs 13.0 (28/216) | 0.02a | 0.53 (0.31–0.90) |
| P | 7.3 (32/438) vs 10.3 (4/39) | 0.52b | 0.69 (0.23–2.06) | ||
| 2nd | P | 9.9 (13/131) vs 20.0 (21/105) | 0.07 | 0.49 (0.22–1.06) | |
| P | 10.8 (10/93) vs 23.1 (3/13) | 0.16 | 0.37 (0.09–1.50) |
P: Proximal splenic artery embolization; D: Distal splenic artery embolization; P + D: Combination of proximal and distal splenic artery embolization; DC III: Clavien-Dindo classification of morbidity for complication III
aChi-square
bFisher’s test
Fig. 2Forest plot of embolization locations (Proximal vs Distal) associated with success rate (a), severe complications (b) and the incidence of DC III (c) in 2nd study set
Fig. 3Forest plot of embolization locations (Proximal vs Combination) associated with success rate (a), severe complications (b) and the incidence of DC III (c) in 2nd study set
Comparisons of clinical outcomes between coil and gelfoam
| Outcome | Study set | Coil (%) | Gelfoam (%) |
|
|
|---|---|---|---|---|---|
| Success rate | 1st | 92.4 (391/423) | 83.9 (94/112) | 0.0060a | 2.34 (1.26–4.35) |
| 2nd | 87.7 (128/146) | 85.2 (69/81) | 0.39 | 1.41 (0.66–3.03) | |
| Severe complication | 1st | 12.5 (61/487) | 41.6 (42/101) | <0.0001a | 0.20 (0.12–0.32) |
| 2nd | 20.0 (26/130) | 34.2 (25/73) | 0.02 | 0.48 (0.26–0.90) | |
| DC III | 1st | 7.3 (36/493) | 20.9 (23/110) | <0.0001a | 0.30 (0.17–0.53) |
| 2nd | 10.2 (13/128) | 21.5 (17/79) | 0.03 | 0.43 (0.20–0.92) |
DC III Clavien-Dindo classification of morbidity for complication III
aChi-square test
Fig. 4Forest plot of different embolic materials (Coil vs Gelfoam) associated with success rate (a), severe complications (b) and the incidence of DC III (c) in 2nd study set